title: [Are there pulmonary vascular or respiratory effects of prostaglandin vehicles (ethanol, glycine buffer) after intravenous infusion or inhalation?].
abstract: BACKGROUND
  Infusion or inhalation of prostaglandins PGE1 and PGI2 is used to reduce vascular resistance. PGE1 and PGI2 are dissolved in ethanol and glycine buffer, respectively. Each vehicle may cause dose-dependent haemodynamic and respiratory side effects. This study was performed to examine the role of low-dose ethanol and glycine buffer as used for the infusion and inhalation of PGE1 and PGI2.
  
  
  METHODS
  Two groups of pigs (ethanol and glycine group, n = 9 each) were anaesthetised and ventilated mechanically. Ethanol was given at 0.14 mg/kg/min by infusion and 0.12 mg/kg/min as aerosol, glycine buffer was infused at 3.8 microg/kg/min and inhaled at 3.1 microg/kg/min, respectively. Haemodynamic and respiratory data were recorded before and after application.
  
  
  RESULTS
  Neither infusion nor inhalation of ethanol or glycine buffer caused significant changes in systemic and pulmonary haemodynamics, right heart function, oxygenation or ventilation.
  
  
  CONCLUSIONS
  The effect of inhaled or intravenously infused PGE1 and PGI2 is not influenced by their preparations containing ethanol or glycine buffer.
authors.affiliation: Klinik für Anästhesiologie und operative Intensivmedizin, Albert-Schweitzer-Krankenhaus Northeim. michael.bund@ask-northeim.de
authors.forename: M
authors.initials: M
authors.lastname: Bund
authors.forename: M
authors.initials: M
authors.lastname: Winterhalter
authors.forename: C
authors.initials: C
authors.lastname: Weilbach
authors.forename: S
authors.initials: S
authors.lastname: Piepenbrock
mesh_terms: D000280:Administration, Inhalation; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002021:Buffers; D004305:Dose-Response Relationship, Drug; D011464:Epoprostenol / Q000008:administration & dosage / Q000009:adverse effects*; D000431:Ethanol / Q000009:adverse effects*; D005260:Female; D005998:Glycine / Q000009:adverse effects*; D006439:Hemodynamics / Q000187:drug effects; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007262:Infusions, Intravenous; D010100:Oxygen / Q000097:blood*; D014677:Pharmaceutical Vehicles / Q000009:adverse effects*; D013552:Swine; D014655:Vascular Resistance / Q000187:drug effects*; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000959:Antihypertensive Agents; D002021:Buffers; D014677:Pharmaceutical Vehicles; D014665:Vasodilator Agents; D000431:Ethanol; D011464:Epoprostenol; D000527:Alprostadil; D010100:Oxygen; D005998:Glycine